Drug Combination Details
| General Information of the Combination (ID: C82644) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | PHA665752 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Male nude mice (4-6 weeks) were inoculated subcutaneously with human liver cancer cell lines Huh7. | |||||
| Experimental
Result(s) |
Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Mol Biol Rep. 2013 Jul;40(7):4203-9. | |||
